A new, daily pill could help treat symptoms of endometriosis. The new pill, linzagolix, has just been approved for daily use by NICE after clinical trials, claiming it to be a more ‘convenient’ treatment to help people manage their condition more easily at home. The treatment follows the combination therapy pill relugolix, which was approved earlier in March.
- Endometriosis: what the practice nurse needs to know
- Educating and training nurses key to timely diagnosis of endometriosis
- The hidden price of women's pain
‘We're pleased to recommend linzagolix as a new treatment option for endometriosis,’ said Helen Knight, director of medicines evaluation at NICE. ‘As a once-daily tablet taken at home, it offers a convenient way for people with endometriosis to manage their condition and helps to ease pressure on NHS services. Linzagolix is a valuable addition to the options available for this often painful and disruptive condition.’
The new treatment is available alongside a combination of other therapies. The pill works by blocking the hormones, like oestrogen, contributing to endometriosis symptoms such as severe pain and heavy periods. The distribution of the pill is claimed to align with the NHS’ Plans for Change, by cutting down diagnostic and waiting times.
‘This could be a game-changer for thousands of women battling endometriosis, which can be a debilitating and life-limiting condition,’ said Baroness Merron, Women’s Health Minister. ‘After years of neglect in women’s health, we are turning the tide - backing new treatments like linzagolix, cutting diagnosis times and slashing waiting lists. Through our Plan for Change, we will make sure the NHS is there for all women when they need it.’
Endometriosis, a long-term condition where cells similar to those in the lining of the womb (uterus) grow in other parts of the body. causes chronic and debilitating pain and fatigue, and affects around 1.5 million women in the UK.